Amyloidosis physiopathology

Joint Bone Spine

Volumn 67, Issue 3, 2000, Pages 164-170

  Grateau, Gilles ^a  

^a HÔTEL DIEU   (France)

Author keywords

Aggregation; Amyloidosis; Beta sheet; Folding; Protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN;

AMYLOIDOSIS; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN METABOLISM; REVIEW;

AMYLOIDOSIS; HUMANS;

EID: 0034129897     PISSN: 11698446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. e éd. Paris : Ll.immarion Médecine-Sciences ; 2000. p. 1279-308.
2. droh VI, Receveur V. Le repliement raté des protéines. La Recherche 1999 ; 325 : 51-3.
3. Orpiszewski J, Benson. Fibrillogenèse. In : Grateau G, Benson MIX Delpech M, ed. Les amyloses. Paris : Flammarion Médecine-Sciences ; 2000. p. 63-9-1.
4. Westermark P, Araki S, Benson MO, Cohen AS, Lrangione B, M.Mers CL, et al. Nomenclature of amyloid fihril proteins. Report ot the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9 1998. Amyloid. Int J Exp Clin Invest 1999 ; 6 : 63-7.
5. Teng M, Buxbaurn JN. Transgenic mice in amyloid research : an interpretative review. Amyloid. Int J Exp Clin Invest 1996 ; 3 : 187-208.
6. Vincent C, Revillard JP, Galiand M, Traeger J. Serum beta2microglobulin in hemodialyzed patients. Nephron 1978 : 21 : 260-8.
7. Scheinberg MA, Benson MD. SAA amyloid protein levels in amyloid-prone chronic inflammatory disorders. Lack of association with amyloid disease. J Rheumatol 1980 ; 7 : 724-6.
8. Preud'homme |E, Ganeval D, Grunfeld JP, Striker I., Brouet |C. Immunoglobulin synthesis in primary and myeloma amyloidosis. Clin Exp Immunol, 1988 ; 73 : 389-94.'
9. Rader DJ, Cregg RE, Meng MS, Schaefer JR, Zech EA, Benson ML), et al. In vivo metabolism of a mutant apolipoprotein, ApoAI Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Eipid Res 1992 ; 33 : 755-63.
10. Benson ML), Kluve-Beckerman B, Eiepnieks JJ, Murrell |R, Hanes D, Uemichi I. Metabolism of amyloid proteins. Ciba Found Symposium 1996 ; 104-13 ; discussion 113-8.
11. Solomon A, Erangione B, Eranklin EC. Bence-Jones proteins and light chains of immunoglobulin: preferential association of the V lamda VI subgroup of human light chains with amyloidosis AE (lambda). J Clin Invest 1982 ; 70 : 453-60.
12. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Hematol Oncol Clin North Am 1992 : 6 : 323-46.
13. Eiepnieks Jj, Kluve-Beckerman B, Benson ML). Characterization of amyloid A protein in human secondary amyloidosis: the predominant deposition of serum amyloid AE Biochim Biophys Acta 1995 ; 1270 : 81-6.
14. Westermark P, Sletten K, Westermark GT, Raynes J, McAdam KP. A protein AA-variant derived from a novel serum AA protein, SAA1, in an individual from Papua New Guinea. Biochem Biophys Res Commun 1996 ; 223 : 320-3.
15. Anders RE, Price MA, Wilkey IS, Husby G, Takitaki E Natvig JB, et al. Amyloid fibril protein AA in Papua New Guinean amyloidosis. Clin Exp Immunol 1976 : 24 : 49-53
16. Baba S, Masago SA, Takahashi T, Kasama E Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid A, SAA1 : genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995 ;4 : 1083-7.
17. Paunio I, Kangas H, Heinonen O, Buc-Caron MH, Robert JJ, Kaasincn S, et al. Cells of the neuronal lineage play a major role in the generation of amyloid precursor fragments in gelsolinrelated amyloidosis. J Biol Chem 1998 ; 273 : 19319-24.
18. Miyata T, Oda O, Inagi R, lida Y, Araki N, Yamada N, et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993 ; 92 : 1243-52.
19. Kelly JW. 'Ehe alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998 ; 8 : 101-6
20. Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992 ; 31 : 8654-60.
21. McCutchen SE, Eai Z, Miroy GJ, Kelly JW, Colon W Comparison of lethal and non-lethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995 ; 34 : 13527-36.
22. Serpell LG, Sunde M, Fraser PE, Luther PK, Morris EP, Sangren O, et al. The examination of the structure of the transthyrenn amyloid fibril by image reconstruction from electron micrographs. J Mol Biof 1995 ; 254 : 1 13-8.
23. Helms ER, Wentzel R. Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.J Mol Biol 1996:257 :7_86.
24. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997 ; 50 : ] 83-242.
25. Decourt C, Touchard G, Preud'homme JE, Vidai R, Beaufils H, Diemen MC., et al. Complete primary sequences of two lambda immunoglobulin light chains in myelomas with nonamyloid (Randall-type) light chain deposition disease. Am ( Pathol 1998 ; 153': 313-8.
26. Pan KM, Baldwin M, Nguyen |, Gasset M, Serban A, Groth D, et al. Conversion of -helices into -sheets features in the formation of the scrapie priori proteins. Proc Natl Acad Sei USA 1993:90: 10962-6.
27. Wisniewski T, Aucoutuner P, Soto C, Frangione B. The prionoses and other conformational disorders. Amyloid. Int J Exp Clin Invest 1998 ; 5 : 212-24.
28. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WE, Fraser PE, et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997 : 385 : 787-93
29. Arvinte T, Cudd A, Drake AE Ehe structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 1993 ; 268 : 6415-22.
30. Jarrett JT, Lanstmry PT. Seeding 'One-dimensional crystallisation' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993 : 73 : 1055-8.
31. Feplow DB. Structural and kinetic features of amyloid -protein fibrillogenesis. Amyloid. Int J Exp Clin Invest 1998 ; 5 : 121-42.
32. Eavie G, Zucker-Franklin D, Franklin EC. Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med 1978 ; 148 : 1020-31.
33. Migita K, Eguchi K, Tsukada T, Kawabe Y, Takashima H, Mine M, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Eab Invest 1996 ; 75 : 371-5.
34. Shirahama T, Cohen AS. Intralysosomal formation of amyloid fibrils. Am J Pathol 1975 ; 81 : 101-6.
35. Yamada T, Eiepnieks JJ., Kluve-Beckerman B, Benson Ml). Cathepsin B generates the most common form of amyloid A (76 residues) as a degradation product from serum amyloid A. Scand J Immunol 1995 ; 41 : 94-7.
36. Chan SE, Chronopoulos S, Murray J, Eaird DW, AliKhan Z. Selective localization of murine ApoSAAl/SAA2 in endosomes-lysosomes in activated macrophages and their degradation procucts. Amyloid. Int I Exp Clin Invest 1997 ; 4 : 40-8.
37. Kisilevsky R, Narindrasorasak S, Tape C., Tan R, Boudreau E. During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post- fibrillogenic event? Amyloid. Int J Exp Clin Invest 1994 ; 1 : 174-83.
38. Miura K, Shirasawa H. Amyloid A (AA) fibril formation in renal tubules occurs intracytoplasmically, possibly at the site of membrane assembling structures. Amyloid. Int J Exp Clin Invest 1994 ; l : 107-13.
39. Olsen KE, Sletten K, Sandgren C), Olsson H, Myrvold K, Westcrmark P. Giant cells in AI. amyloidosis: sign of localized fibril formation? Amyloid. Int J Exp Clin Invest 1999 ; 6 : 89-97.
40. Kisilcvsky R, Gruys E, Shirahama T. Does amyloid enhancing factor (AEF) exists? Is AEF a single biological entity? Amyloid. Int J Exp Clin Invest 1995 ; 2 : 128-33.
41. Gonnerman WA, Kandel R, Cathcart ES. Amyloid enhancing factor is produced by rats and amyloid-resistant CE/f mice. Lab Invest 1996 ; 74 : 259-64.
42. Tennent GA, Lovat EB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sei USA 1995 ; 92 : 42991303.
43. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med 1997 ; 3 : 855-9.
44. Lyon AW, Narindrosorasak S, Young ID. Codeposition of basement membrane components during the induction of murine splenic AA amyloid. Eab Invest 1991 ; 64 : 785-90.
45. Ailles E, Kisilevsky R, Young ID. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidosis. Eab Invest 1993 ; 69 : 443-8.
46. Wisniewski I, Frangione B. Apolipoprotein F,: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Eett 1992 ; 135 : 235-8.
47. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Ciaskeil PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allc'le and the risk of Alzheimer's disease in late-onset families. Science 1993 ; 261 : 921-3.
48. Kindy MS, De Beer EC, Markesberyl WR, Pras M, Aksentijevitch I, Kastner D, et al. Apolipoprotein E genotypes in AA and AE amyloidosis. Amyloid. Int J Exp Clin Invest 1995 ; 2 :159-62.
49. Lovat EB, Booth SE, Booth DR, Madhoo S, Holmgren G, Hawkins PN, et al. Apolipoprotein F,4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. Amyloid. Int J FJcp Clin invest 1995 ; 2 : 163-6.
50. Hasegawa H, Nishi S, Ito S. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis Rheum 1996 ; 39 : 1728-32.
51. Gejyo F, Suzuki S, Kimura H, Imura K, Hasegawa H, Arakawa M. Increased risk of dialysis-related amyloidosis in patients with the apolipoprotein E4 allele. Amyloid. Int J Exp Clin Invest 1997; 4 : 13-7.
52. Soto C, Sigurdsson EM, Morelli E, Kumar RA. Castano EM, Frangione B. Beta-sheet breaker peptides inhibit hbrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998 ; 4 : 822-6.
53. Kisilevsky R, Eemieux LJ, Fraser PJ, Kong X, Hultin PC, S/are k WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995 ; 1 : 143-8.
54. Grateau G, Benson MD, Delpech M, ed. Ees amyloses. Paris : Fiammarion Médecine Science ; 2000.